Search
Selected Filter
Filter Results
Displaying 181–190 of 196 news results
-
Jul 16, 2018
Dr. Kelley brings more than 25 years of experience in developing, identifying, and advancing life science technologies to this leadership role at FFB
-
Jun 18, 2018
Three-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments
-
Jun 15, 2018
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development
-
Jun 8, 2018
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
-
Jan 18, 2018
The Assistance Fund Opens New Program for Inherited Retinal Diseases
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
-
Jan 9, 2018
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
Oct 12, 2017
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Apr 13, 2016
Foundation Fighting Blindness Announces Leadership Succession Plan After 45 Year Legacy
David Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
-
Oct 1, 2015
The Challenge Continues: FFB Chairman Gordon Gund is Interviewed on CNBC
In a recent interview with CNBC’ s Brian Sullivan, during a tech-investor conference in Nantucket, Gordon explained why this is such a crucial time in retinal-research history.
-
Jan 14, 2014
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Five of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.